Pharvaris N.V.
PHVS
Price:
$21.01
Market Cap:
$1.02B
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Neth...[Read more]
Industry
Biotechnology
IPO Date
2021-02-05
Stock Exchange
NASDAQ
Ticker
PHVS
The ROE as of September 2024 (TTM) for Pharvaris N.V. (PHVS) is -36.89%
According to Pharvaris N.V.’s latest financial reports and current stock price. The company's current ROE is -36.89%. This represents a change of 264.47% compared to the average of -10.12% of the last 4 quarters.
Pharvaris N.V. (PHVS) Historical ROE (quarterly & annually)
How has PHVS ROE performed in the past?
The mean historical ROE of Pharvaris N.V. over the last ten years is -36.43%. The current -36.89% ROE has changed 1.27% with respect to the historical average. Over the past ten years (40 quarters), PHVS's ROE was at its highest in in the June 2023 quarter at 0.42%. The ROE was at its lowest in in the March 2018 quarter at -87.10%.
Average
-36.43%
Median
-27.13%
Minimum
-87.10%
Maximum
0%
Pharvaris N.V. (PHVS) ROE by Quarter and Year
Discovering the peaks and valleys of Pharvaris N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 145.29%
Maximum Annual ROE = 0%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -87.10%
| Year | ROE | Change |
|---|---|---|
| 2023 | -25.71% | -49.73% |
| 2022 | -51.14% | 145.29% |
| 2021 | -20.85% | -23.15% |
| 2020 | -27.13% | -37.02% |
| 2019 | -43.08% | -50.55% |
| 2018 | -87.10% | -Infinity% |
Pharvaris N.V. (PHVS) Average ROE
How has PHVS ROE performed in the past?
The current ROE of Pharvaris N.V. (PHVS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.57%
5-year avg
-33.58%
10-year avg
-36.43%
Pharvaris N.V. (PHVS) ROE vs. Peers
How is PHVS’s ROE compared to its peers?
Pharvaris N.V.’s ROE is greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than MediciNova, Inc. (-13.37%), greater than PepGen Inc. (-62.74%), greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Rezolute, Inc. (-60.90%),
| Company | ROE | Market cap |
|---|---|---|
| -21.96% | $78.05M | |
| -47.03% | $553.25M | |
| -13.37% | $89.26M | |
| -62.74% | $298.85M | |
| -33.08% | $172.94M | |
| -42.61% | $575.83M | |
| -54.72% | $31.19M | |
| -70.40% | $344.30M | |
| -18.48% | $313.68M | |
| -48.25% | $92.65M | |
| -42.81% | $83.00M | |
| -57.89% | $777.08M | |
| -27.13% | $1.07B | |
| -122.97% | $54.20M | |
| -8.78% | $2.56B | |
| -60.90% | $285.09M |
Build a custom stock screener for Pharvaris N.V. (PHVS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pharvaris N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Pharvaris N.V. (PHVS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Pharvaris N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Pharvaris N.V.'s ROE?
How is the ROE calculated for Pharvaris N.V. (PHVS)?
What is the highest ROE for Pharvaris N.V. (PHVS)?
What is the 3-year average ROE for Pharvaris N.V. (PHVS)?
What is the 5-year average ROE for Pharvaris N.V. (PHVS)?
How does the current ROE for Pharvaris N.V. (PHVS) compare to its historical average?